Radezolid salts and polymorphic forms thereof
    22.
    发明授权
    Radezolid salts and polymorphic forms thereof 有权
    拉地唑胺及其多晶型物

    公开(公告)号:US09126991B2

    公开(公告)日:2015-09-08

    申请号:US13998122

    申请日:2013-10-02

    IPC分类号: C07D413/12

    CPC分类号: C07D413/12

    摘要: Disclosed are compounds of Formula 1a, wherein HX represents HBr, phosphoric acid, sulfuric acid, methanesulfonic acid or ethanesulfonic acid, and polymorphs thereof.

    摘要翻译: 公开了式1a的化合物,其中HX表示HBr,磷酸,硫酸,甲磺酸或乙磺酸,及其多晶型物。

    Radezolid salts and polymorphic forms thereof
    23.
    发明申请
    Radezolid salts and polymorphic forms thereof 审中-公开
    拉地唑胺及其多晶型物

    公开(公告)号:US20140100254A1

    公开(公告)日:2014-04-10

    申请号:US13998122

    申请日:2013-10-02

    IPC分类号: C07D413/12

    CPC分类号: C07D413/12

    摘要: Disclosed are compounds of Formula 1a, wherein HX represents HBr, phosphoric acid, sulfuric acid, methanesulfonic acid or ethanesulfonic acid, and polymorphs thereof.This invention also provides polymorph forms of oxazolidinone salts of Formula 1b: wherein HY represents HCl, HBr, phosphoric acid, sulfuric acid, methanesulfonic acid or ethanesulfonic acid.Also disclosed are compositions containing one or more compounds of Formula 1a, methods for controlling a microbial infection in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula 1a, and methods for preparing compounds of Formula 1b.

    摘要翻译: 公开了式1a的化合物,其中HX表示HBr,磷酸,硫酸,甲磺酸或乙磺酸,及其多晶型物。 本发明还提供式1b的恶唑烷酮盐的多晶型:其中HY表示HCl,HBr,磷酸,硫酸,甲磺酸或乙磺酸。 还公开了含有一种或多种式1a化合物的组合物,用于控制哺乳动物微生物感染的方法,包括向哺乳动物施用治疗有效量的式1a化合物,以及制备式1b化合物的方法。

    Particulates of a CRTH2 antagonist
    24.
    发明授权
    Particulates of a CRTH2 antagonist 有权
    CRTH2拮抗剂的颗粒

    公开(公告)号:US08507005B2

    公开(公告)日:2013-08-13

    申请号:US12665706

    申请日:2008-06-18

    申请人: Tai Wei Ly Hui-Yin Li

    发明人: Tai Wei Ly Hui-Yin Li

    CPC分类号: C07D239/48 Y10T428/2982

    摘要: Provided herein are particulates of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid in amorphous or crystalline forms, processes for their preparation, pharmaceutical compositions comprising them, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.

    摘要翻译: 本文提供了无定形或结晶形式的{4,6-双(二甲基氨基)-2-(4-(4-(三氟甲基)苯甲酰氨基)苄基)嘧啶-5-基}乙酸的颗粒,其制备方法,药物 包含它们的组合物及其用于治疗,预防或改善CRTH2介导的病症或疾病的一种或多种症状的方法。

    PARTICULATES OF A CRTH2 ANTAGONIST
    26.
    发明申请
    PARTICULATES OF A CRTH2 ANTAGONIST 有权
    CRTH2拮抗剂的颗粒

    公开(公告)号:US20110052701A1

    公开(公告)日:2011-03-03

    申请号:US12665706

    申请日:2008-06-18

    申请人: Tai Wei Ly Hui-Yin Li

    发明人: Tai Wei Ly Hui-Yin Li

    CPC分类号: C07D239/48 Y10T428/2982

    摘要: Provided herein are particulates of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid in amorphous or crystalline forms, processes for their preparation, pharmaceutical compositions comprising them, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.

    摘要翻译: 本文提供了无定形或结晶形式的{4,6-双(二甲基氨基)-2-(4-(4-(三氟甲基)苯甲酰氨基)苄基)嘧啶-5-基}乙酸的颗粒,其制备方法,药物 包含它们的组合物及其用于治疗,预防或改善CRTH2介导的病症或疾病的一种或多种症状的方法。

    Novel stable compositions of water and oxygen sensitive compounds and their method of preparation
    27.
    发明申请
    Novel stable compositions of water and oxygen sensitive compounds and their method of preparation 审中-公开
    水和氧敏感化合物的新型稳定组合物及其制备方法

    公开(公告)号:US20050288257A1

    公开(公告)日:2005-12-29

    申请号:US11166937

    申请日:2005-06-23

    IPC分类号: A61K31/675 A61K47/06

    CPC分类号: A61K31/675 A61K47/06

    摘要: The present application described a new formulation for oxygen and/or water sensitive compounds with an inert material such as paraffin. The new formulation provides stability for the oxygen and/or water sensitive compounds in the air and can be handled easily. The new formulation of the present invention is useful as ligands and/or catalysts for preparation of pharmaceuticals, agrochemical, other fine chemicals and other synthetic compounds.

    摘要翻译: 本申请描述了具有惰性物质如石蜡的氧和/或水敏化合物的新制剂。 新配方为空气中的氧和/或水敏感化合物提供稳定性,并且可以容易地处理。 本发明的新配方可用作制备药物,农药,其他精细化学品和其它合成化合物的配体和/或催化剂。

    Polymorphic forms of 6-11 bicyclic ketolide derivatives
    28.
    发明申请
    Polymorphic forms of 6-11 bicyclic ketolide derivatives 有权
    6-11双环酮内酯衍生物的多形态

    公开(公告)号:US20050203035A1

    公开(公告)日:2005-09-15

    申请号:US11057476

    申请日:2005-02-14

    CPC分类号: C07H17/08

    摘要: The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing the various polymorphic forms in pure form or in combination with one another. The present invention also provides pharmaceutical compositions and formulations comprising the polymorphic and amorphous forms and methods of treating bacterial infections by administering the pharmaceutical compositions to a subject in need of such treatment.

    摘要翻译: 本发明包括具有不同物理性质的EP-13420多晶型形式:I型,II型,Ia型和一水合物和无定型EP-13420。 在本发明的另一个实施方案中,提供了以纯形式或彼此组合生产各种多晶形式的方法。 本发明还提供药物组合物和制剂,其包含多形态和无定形形式以及通过将药物组合物施用于需要这种治疗的受试者来治疗细菌感染的方法。

    Efficient method for the conversion of nitriles to amidines and species thereof
    29.
    发明授权
    Efficient method for the conversion of nitriles to amidines and species thereof 失效
    将腈转化为脒及其物质的有效方法

    公开(公告)号:US06245914B1

    公开(公告)日:2001-06-12

    申请号:US09346409

    申请日:1999-07-01

    IPC分类号: C07D26108

    摘要: The present invention relates to processes for the conversion of nitrites to amidines in the preparation of compounds which are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex. The compounds described herein are potent thrombolytics and useful for the inhibition of platelet aggregation in the treatment of thromboembolic disorders.

    摘要翻译: 本发明涉及在制备作为血小板糖蛋白IIb / IIIa纤维蛋白原受体复合物的拮抗剂的化合物中将亚硝酸盐转化成脒的方法。 本文所述的化合物是有效的溶栓剂,并且可用于抑制血小板聚集以治疗血栓栓塞性疾病。

    Asymmetric R and S warfarin and its analogs
    30.
    发明授权
    Asymmetric R and S warfarin and its analogs 失效
    不对称R和S华法林及其类似物

    公开(公告)号:US5856525A

    公开(公告)日:1999-01-05

    申请号:US950018

    申请日:1997-10-14

    CPC分类号: C07D311/56

    摘要: The present invention provides a novel process for making compounds of formula 2a or 2b or pharmaceutically acceptable salts thereof, ##STR1## wherein R.sub.1 is selected from the group consisting of phenyl and phenyl substituted with at least one group selected from NO.sub.2 and halogen;R.sub.2 is H;R.sub.3 is selected from the group consisting of C.sub.1-4 alkyl, phenyl, and benzyl; and,R.sub.4 is selected from the group consisting of H and halogen;which comprises the steps of:a) oxidizing a racemate of formula 2 or a salt thereof to form a dehydro-compound of formula 3, ##STR2## wherein R.sub.5 is selected from the group consisting of H, CH.sub.3, benzyl, C.sub.2-8 acyl Na, Li and K; and,b) asymmetrically hydrogenating a compound of formula 3 in the presence of a chiral phosphine catalyst to form a compound of formula 2a or 2b.

    摘要翻译: 本发明提供制备式2a或2b化合物或其药学上可接受的盐的新方法,其中R 1选自苯基和至少被取代的苯基 一个选自NO2和卤素的基团; R2为H; R 3选自C 1-4烷基,苯基和苄基; 并且R 4选自H和卤素; 其包括以下步骤:a)氧化式2的外消旋物或其盐以形成式3的脱氢化合物,由H,CH 3,苄基,C 2-8酰基Na,Li和K组成的图像 ; 和b)在手性膦催化剂的存在下不对称地氢化式3的化合物以形成式2a或2b的化合物。